ESPERION Reports Third Quarter 2020 Financial Results and Provides Company Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Esperion Therapeutics (ESPR) Tops Q3 EPS by 37c
November 2, 2020 4:43 PM ESTEsperion Therapeutics (NASDAQ: ESPR) reported Q3 EPS of ($3.07), $0.37 better than the analyst estimate of ($3.44). Revenue for the quarter came in at $3.8 million versus the consensus estimate of $5.17 million.
For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.
... More